Brief: Vincerx Pharma Doses First Patient In The Phase 1 Clinical Trial Evaluating Vip943
14/09/2023 12:17
Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA DOSES FIRST PATIENT IN THE PHASE 1 CLINICAL
TRIAL
EVALUATING VIP943
* VINCERX PHARMA INC- EXPECT TO REPORT PRELIMINARY SAFETY
AND
PHARMACOLOGY DATA FROM VIP943 PHASE 1 STUDY IN 2024
Source text for Eikon: ID:nGNX7DQcG
Further company coverage: VINC.O
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign